Remote Patient Monitoring - Opportunities for Pharma - Thematic Research
Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, carers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary. RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures.
This report assesses how RPM, such as wearables, portables, mobile health (mHealth), and telemedicine can be used across the pharma value chain from drug development, post approval, sales and marketing, and end users. It provides an evaluation of the main opportunities and challenges to the use of RPM, as well as an overview of the current landscape, including changes to regulatory and reimbursement policies. The report also includes an analyses of RPM-related deals and jobs and the impact of COVID-19 on virtual trials, telemedicine, and physician use of remote monitoring technologies. Pharma-specific case studies in RPM are also included.
Summary
Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, carers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary. RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures.
This report assesses how RPM, such as wearables, portables, mobile health (mHealth), and telemedicine can be used across the pharma value chain from drug development, post approval, sales and marketing, and end users. It provides an evaluation of the main opportunities and challenges to the use of RPM, as well as an overview of the current landscape, including changes to regulatory and reimbursement policies. The report also includes an analyses of RPM-related deals and jobs and the impact of COVID-19 on virtual trials, telemedicine, and physician use of remote monitoring technologies. Pharma-specific case studies in RPM are also included.
Scope
- Key players in the RPM space, with a focus on technology providers and pharma adopters where applicable. The report focuses on any remote monitoring technologies that big pharma has integrated into RPM projects and solutions.
- Thematic briefing which explores different types of RPM in more detail, including wearables, portable devices, mHealth, and telemedicine.
- Key trends impacting the RPM space. Industry trends include the impact of COVID-19 on clinical trials and digital health innovation, how RPM is driving value-based care and increased patient empowerment, and the impact of increased burden of chronic diseases. Technology trends include the role of wearable technology, mHealth, telemedicine, Big Data and artificial intelligence (AI), and cybersecurity. Regulatory trends include the lack of regulatory frameworks for virtual trials and guidelines issues during COVID-19 to support continuation of clinical research.
- Opportunities and challenges for pharma: Opportunities include such changing regulations, continued acceptance of digital technologies, increased collaborations, patient support programs, and value-based care. Challenges include data privacy and security, interoperability, design challenges, and skills shortages.
- Value chain looking at how RPM can be used across the pharma value chain, from drug discovery and development, post drug approval, sales and marketing, and patient use.
- Industry analysis with an analysis of virtual trials including those generating real-world evidence, use of telemedicine during the pandemic, analysis of mobile apps from pharma, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
- Profiles of private and public companies in the RPM space.
Reasons to Buy
- Assess who the leading technology players are in the RPM space, as well as leading pharma adopters.
- See examples of how pharma companies are integrating remote monitoring technologies into their value chains.
- Understand what trends are driving the use of RPM, and also what opportunities and challenges exist for pharma in the space.
- See how the RPM landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships and funding deals, as well as a jobs analysis.
- Assess the impact of COVID-19 on the use of remote monitoring technologies by physicians.
Table of Contents
- Executive Summary
- Players
- Thematic Briefing
- Trends
- Healthcare Trends
- Technology Trends
- Regulatory trends
- Macroeconomic Trends
- Opportunities and Challenges for Pharma
- Value Chain
- Drug Discovery and Development
- Post Drug Approval
- Sales and Marketing
- End Users
- Industry Analysis
- Virtual Clinical Trials Analysis
- Use of RPM-Derived Real-World Evidence in Post-Marketing Studies
- Increased Use of Telemedicine During the COVID-19 Pandemic
- Analysis of Mobile Apps from Pharma
- Analysis of RPM-Related Jobs in Pharma
- Physician Trends in Remote Monitoring Technologies and the Impact of COVID-19 on Usage
- Deals Analysis
- Mergers and Acquisitions
- Strategic Partnerships
- Funding Deals
- Pharma Case Studies
- Genentech Telemedicine-Based Patient Support Programs
- Evidation and Merck: Digital Monitoring with Focus on Alzheimer’s Disease
- Biobeat Collaborates with Amwell and Amgen to Offer Comprehensive Wearable RPM Services
- Roche Leads the Biopharmaceutical Industry in Terms of Digital Biomarker Research and Investment
- Jobs Analysis
- Healthcare Industry Polls
- Social Media Influencers
- Companies
- Public Pharma Companies
- Private Pharma Companies
- Public Technology Companies
- Private Technology Companies
- Appendix
- Abbreviations
- Further Reading
- Related Reports
- Bibliography
- About the Authors
- Our Thematic Research Methodology
- About the Publisher
- Contact the Publisher
List of Tables
Table 1: Healthcare Trends in the RPM Space
Table 2: Technology Trends in the RPM Space
Table 3: Regulatory Trends in the RPM Space
Table 4: Macroeconomic Trends in the RPM Space
Table 5: Examples of Pharma Companies Utilizing Digital Biomarkers in Drug Development
Table 6: Examples of Pharma Companies Using Virtual Trials
Table 7: Examples of Telemedicine Players in the US and Europe
Table 8: Examples of Pharma Mobile Apps for Patients
Table 9: Examples of M&A in the RPM Space, 2018-2021
Table 10: Examples of Strategic Partnerships in the RPM Space
Table 11: Biopharmaceutical Industry Partnerships Related to RPM
Table 12: Examples of Large Funding Deals in the RPM Space Since Q1 2020
Table 13: Examples of Public Pharma and MedTech Companies in the RPM Space
Table 14: Examples of Private Pharma Companies in the RPM Space
Table 15: Examples of Public Technology Companies in the RPM Space
Table 16: Examples of Private Technology Companies in the RPM Space
List of Figures
Figure 1: Who Are the Leading Players in the RPM Space?
Figure 2: Where Remote Monitoring Technologies Can Be Used Across the Pharma Value Chain
Figure 3: Examples of Companies Developing and Utilizing Digital Biomarkers
Figure 4: Examples of Companies Providing and Utilizing Virtual Trial Platforms
Figure 5: Examples of Companies in the Telemedicine Space
Figure 6: The Proportion of Trials Utilizing Virtual or Digital Components Has Increased Steadily Since 2004
Figure 7: eDiary Is the Most Common Type of Virtual or Digital Component Used in Trials
Figure 8: Metabolic Disorders Is the Leading Therapy Area for Trials Utilizing Virtual or Digital Components
Figure 9: Top 10 Pharma Sponsors of Trials with Virtual or Digital Components
Figure 10: Top Pharma Sponsors or Collaborators of Virtual Trials With RWE Element
Figure 11: Metabolic Disorders Is the Leading Therapy Area for Virtual Trials Related to RWE
Figure 12: Monthly Downloads and Retention for Leading Telemedicine Apps for Patients since January 2020
Figure 13: Assessment of Pharma Activity in the mHealth Space
Figure 14: Trends in RPM-Related Job Posting By Pharma, 2019 - 2021
Figure 15: Examples of Leading Pharma Companies Posting Jobs Related to RPM
Figure 16: Breakdown of RPM Jobs By Type and By Company
Figure 17: Telemedicine and Wearable Devices Used Commonly By Physicians to Monitor Patients Remotely
Figure 18: Preference for In-Person Care is a Leading Patient Barrier to Using Remote Monitoring Technologies
Figure 19: Patients With Chronic Diseases Most Likely to Use Remote Monitoring Technologies
Figure 20: Increased Use of Telemedicine and Wearable Devices By Physicians During the COVID-19 Pandemic
Figure 21: BioBeat Wearable Wristwatch and Patch
Figure 22: Roche’s Floodlight App Contains Tests That Measure Brain Function, Hand Function, and Mobility
Figure 23: Industry Perspective on Where RPM Best Supports the Pharma Value Chain
Figure 24: Main Benefit of Pharma Integrating RPM and Digital Tools into Trials
Figure 25: Barriers to Adopting Software-enabled Practices in Clinical Trials
Figure 26: Design Challenges When Considering RPM Technologies/ Devices
Figure 27: RPM Trends in the Digital Pharma Influencer Database, August 2020 to August 2021
Figure 28: Examples of Top Posts Related to RPM, 2020-2021
Figure 29: Our Five-Step Approach for Generating a Sector Scorecard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson
- Pfizer
- Roche
- Novartis
- Takeda
- AbbVie
- AstraZeneca
- Sanofi
- GlaxoSmithKline
- Eli Lilly
- AliveCor
- Empatica
- Livongo
- Omron
- Teladoc
- Amwell
- Aural Analytics
- Evidation
- Huma
- Science37
- Medable
- THREAD
- AiCure
- Akili
- Babylon
- Biobeat
- Qardio
- Biofourmis
- Thirty Madison
- Doctolib
- Lightship
- Studies&Me
